Suppr超能文献

多发性硬化中的神经退行性变和脱髓鞘。

Neurodegeneration and demyelination in multiple sclerosis.

机构信息

Division of Neuroimmunology, Department of Neurology, Johns Hopkins University School of Medicine, Baltimore, MD, USA.

Division of Neuroimmunology, Department of Neurology, Johns Hopkins University School of Medicine, Baltimore, MD, USA.

出版信息

Neuron. 2024 Oct 9;112(19):3231-3251. doi: 10.1016/j.neuron.2024.05.025. Epub 2024 Jun 17.

Abstract

Progressive multiple sclerosis (PMS) is an immune-initiated neurodegenerative condition that lacks effective therapies. Although peripheral immune infiltration is a hallmark of relapsing-remitting MS (RRMS), PMS is associated with chronic, tissue-restricted inflammation and disease-associated reactive glial states. The effector functions of disease-associated microglia, astrocytes, and oligodendrocyte lineage cells are beginning to be defined, and recent studies have made significant progress in uncovering their pathologic implications. In this review, we discuss the immune-glia interactions that underlie demyelination, failed remyelination, and neurodegeneration with a focus on PMS. We highlight the common and divergent immune mechanisms by which glial cells acquire disease-associated phenotypes. Finally, we discuss recent advances that have revealed promising novel therapeutic targets for the treatment of PMS and other neurodegenerative diseases.

摘要

进行性多发性硬化症(PMS)是一种免疫起始的神经退行性疾病,目前缺乏有效的治疗方法。尽管外周免疫浸润是复发缓解型多发性硬化症(RRMS)的标志,但 PMS 与慢性、组织受限的炎症和与疾病相关的反应性神经胶质状态有关。疾病相关小胶质细胞、星形胶质细胞和少突胶质细胞谱系细胞的效应功能开始被定义,最近的研究在揭示它们的病理意义方面取得了重大进展。在这篇综述中,我们讨论了导致脱髓鞘、失败性髓鞘再生和神经退行性变的免疫-神经胶质相互作用,重点是 PMS。我们强调了胶质细胞获得与疾病相关表型的常见和不同的免疫机制。最后,我们讨论了最近的进展,这些进展揭示了治疗 PMS 和其他神经退行性疾病的有前途的新治疗靶点。

相似文献

1
Neurodegeneration and demyelination in multiple sclerosis.
Neuron. 2024 Oct 9;112(19):3231-3251. doi: 10.1016/j.neuron.2024.05.025. Epub 2024 Jun 17.
2
Glial Cells as Key Regulators in Neuroinflammatory Mechanisms Associated with Multiple Sclerosis.
Int J Mol Sci. 2024 Sep 4;25(17):9588. doi: 10.3390/ijms25179588.
3
Microglia and Multiple Sclerosis.
Adv Neurobiol. 2024;37:445-456. doi: 10.1007/978-3-031-55529-9_25.
6
Pathology of multiple sclerosis and related inflammatory demyelinating diseases.
Handb Clin Neurol. 2014;122:15-58. doi: 10.1016/B978-0-444-52001-2.00002-9.
7
Myelin-specific multiple sclerosis antibodies cause complement-dependent oligodendrocyte loss and demyelination.
Acta Neuropathol Commun. 2017 Mar 24;5(1):25. doi: 10.1186/s40478-017-0428-6.
8
Toll-Like Receptor 2-Mediated Glial Cell Activation in a Mouse Model of Cuprizone-Induced Demyelination.
Mol Neurobiol. 2018 Aug;55(8):6237-6249. doi: 10.1007/s12035-017-0838-2. Epub 2017 Dec 29.
9
Disease-associated oligodendroglia: a putative nexus in neurodegeneration.
Trends Immunol. 2024 Oct;45(10):750-759. doi: 10.1016/j.it.2024.08.003. Epub 2024 Sep 24.
10
Time-dependent changes in the brain arachidonic acid cascade during cuprizone-induced demyelination and remyelination.
Prostaglandins Leukot Essent Fatty Acids. 2011 Jul;85(1):29-35. doi: 10.1016/j.plefa.2011.04.001. Epub 2011 May 6.

引用本文的文献

1
Activity and Heterogeneity of Astrocytes in Neurological Diseases: Molecular Mechanisms and Therapeutic Targets.
MedComm (2020). 2025 Aug 22;6(9):e70329. doi: 10.1002/mco2.70329. eCollection 2025 Sep.
3
Inflammation's impact on the interaction between oligodendrocytes and axons.
Discov Immunol. 2025 Apr 29;4(1):kyaf008. doi: 10.1093/discim/kyaf008. eCollection 2025.
4
Ferroptosis and Iron Homeostasis: Molecular Mechanisms and Neurodegenerative Disease Implications.
Antioxidants (Basel). 2025 Apr 28;14(5):527. doi: 10.3390/antiox14050527.
5
Novel Emopamil-Binding Protein Inhibitors for Treating Multiple Sclerosis.
ACS Med Chem Lett. 2025 Apr 2;16(5):730-731. doi: 10.1021/acsmedchemlett.5c00163. eCollection 2025 May 8.
7
Biomedical Applications of Gadolinium-Containing Biomaterials: Not Only MRI Contrast Agent.
Adv Sci (Weinh). 2025 May;12(20):e2501722. doi: 10.1002/advs.202501722. Epub 2025 Apr 25.
8
Neuroinflammation: An Oligodendrocentric View.
Glia. 2025 Jun;73(6):1113-1129. doi: 10.1002/glia.70007. Epub 2025 Mar 10.
10
Neuronal guidance signaling in neurodegenerative diseases: Key regulators that function at neuron-glia and neuroimmune interfaces.
Neural Regen Res. 2026 Feb 1;21(2):612-635. doi: 10.4103/NRR.NRR-D-24-01330. Epub 2025 Feb 24.

本文引用的文献

1
Patient iPSC models reveal glia-intrinsic phenotypes in multiple sclerosis.
Cell Stem Cell. 2024 Nov 7;31(11):1701-1713.e8. doi: 10.1016/j.stem.2024.08.002. Epub 2024 Aug 26.
2
Cellular architecture of evolving neuroinflammatory lesions and multiple sclerosis pathology.
Cell. 2024 Apr 11;187(8):1990-2009.e19. doi: 10.1016/j.cell.2024.02.030. Epub 2024 Mar 20.
3
Disease-associated astrocyte epigenetic memory promotes CNS pathology.
Nature. 2024 Mar;627(8005):865-872. doi: 10.1038/s41586-024-07187-5. Epub 2024 Mar 20.
4
Complement Activation Is Associated With Disease Severity in Multiple Sclerosis.
Neurol Neuroimmunol Neuroinflamm. 2024 Mar;11(2):e200212. doi: 10.1212/NXI.0000000000200212. Epub 2024 Feb 14.
6
Diagnostic Performance of Cortical Lesions and the Central Vein Sign in Multiple Sclerosis.
JAMA Neurol. 2024 Feb 1;81(2):143-153. doi: 10.1001/jamaneurol.2023.4737.
9
Molecular basis of anaphylatoxin binding, activation, and signaling bias at complement receptors.
Cell. 2023 Oct 26;186(22):4956-4973.e21. doi: 10.1016/j.cell.2023.09.020. Epub 2023 Oct 17.
10
Effect of tauroursodeoxycholic acid on survival and safety in amyotrophic lateral sclerosis: a retrospective population-based cohort study.
EClinicalMedicine. 2023 Oct 5;65:102256. doi: 10.1016/j.eclinm.2023.102256. eCollection 2023 Nov.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验